North China Pharmaceutical (600812.SS) Earnings Analysis
North China Pharmaceutical (600812.SS) has no confirmed upcoming earnings date. Trailing P/E 51.06.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 600812.SS next report earnings?
No confirmed upcoming earnings date is currently scheduled for 600812.SS. This page updates as the calendar is published.
600812.SS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2025-06-30 | 0.03904 CNY | n/a | n/a | n/a |
| 2024-10-25 | 0.01776 CNY | n/a | n/a | n/a |
600812.SS valuation and analyst view
| Trailing P/E | 51.06 |
|---|---|
| Trailing EPS | 0.09386 CNY |
| Price / book | 1.49 |
| Dividend yield | 0.73% |
| Market cap | 8.25B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is North China Pharmaceutical (600812.SS)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for 600812.SS. This page updates as the calendar is published.
Did 600812.SS beat earnings last quarter?
Consensus estimate data was not available for 600812.SS's 2025-06-30 report.
What is 600812.SS's current P/E ratio and EPS?
600812.SS trades at a trailing P/E of 51.06 on trailing EPS of 0.09385938887355592 CNY.
What do analysts rate 600812.SS?
600812.SS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.